期刊文献+

康心胶囊在冠心病二级预防中的作用

The effects of "Kangxin capsule" on the secondary prevention in patients with coronary heart disease
下载PDF
导出
摘要 目的观察“康心胶囊”在冠心病二级预防中的作用及疗效。方法将493例冠心病病人分为对照组和治疗组,进行了平均3.5年的观察研究。全部入选病例均给予规范的综合治疗,治疗组加服康心胶囊。观察康心胶囊对血脂,心功能、心脏结构及冠心病事件的影响。结果2组患者在平均治疗3.5年后。与治疗前相比,治疗组与对照组的血脂均有明显改善(P〈0.05-〈0.01)、心功能改善(P〈0.01-〈0.05)、左室舒张末径、左室收缩末径、左室舒张末容积、左室收缩末容积、左室射血分数均有改善(P〈0.01),但治疗组优于对照组(P〈0.05)。冠心病事件中,非致死性心肌梗死、心脏性死亡、复发性心绞痛、心力衰竭、需做PTCA/CABG、再住院治疗、心律失常、脑卒中、非心脏性死亡、全因死亡治疗组明显少于对照组(P〈0.05)。2组药物不良反应无统计学差异(P〉0.05)。结论康心胶囊治疗能进一步降低血脂、减轻左心室重构、改善左心功能、减少冠心病事件的发生。 Objective To observe the effects of the " Kangxin capsule" on the secondary prevention in patients with coronary heart disease. Methods 493 patients with coronary heart disease were randomly divided into the "Kangxin capsule" group and the conventional group. All patients were given regular and comprehensive treatment. Before and after average 3.5 years treatment, the blood lipids, heart function, heart structure,and coronary affairs were determined. Results The blood lipids were obviouly lowered in both groups after treatment ( P 〈 0. 05 or P 〈 0. 01 ). The heart function were significantly strengthened ( P 〈 0. 01 or P 〈 0. 05 ), and LVDD, LVSD, LVDV, LVSV, LVEF were improved ( P 〈 0. 01 ), but the "Kangxin capsule" group exceeded the conventional group ( P 〈 0. 05 ). The occurrence of coronary affairs were lower in "Kangxin capsule" group than that in conventional group ( P 〈 0. 05) including non-deadly myocardial infarction,heart death, repeating angina peetoris, heart failure, need to do PTCA/CABG, re-hospitalization treatment, arrhythmia, brain stroke,non - heart death,and all faeturs death. Those of adverse drug reaction had no siguificant difference. Conclusions The" Kangxin capsule" may lower the blood lipids,lighten left ventrieular restructure,improve left ventricular function, and reduce the occurrence of coronary affairs.
机构地区 本溪市中心医院
出处 《中国厂矿医学》 2006年第1期10-12,共3页 Chinese Medicine of Factory and Mine
关键词 冠心病 康心胶囊 二级预防 Coronary heart disease " Kangxin capsule" Secondary prevention
  • 相关文献

参考文献11

  • 1World Heart Statist. China selected rural areas by causes of death ICD - 9[J]. Ammu Statist, 1987 - 1992.
  • 2陈可冀 陈在嘉 高润霖主编.冠心病中医治则、常用中常药及临床应用[A].陈在嘉,高润霖主编.冠心病[M].北京:人民卫生出版社,2002.626-629.
  • 3Heart protection study collaborative Croup. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high -risk indlviduals :a randomized placebo -controlled trial [J]. Lancet,2002,360:7 - 22.
  • 4Perdersen TR. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S)[J]. Lancet, 1994,344 : 1383 - 1389.
  • 5Expert panel on Detection. Evaluation and treatment of high blood cholesterol in adult( ATP Ⅲ)[J]. JAMA ,2001,19:2486 - 2497.
  • 6Grundy SM, Cleeman LI,Bairey - Merz CN ,et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines [J]. Circulation,2004,110:227 -239.
  • 7ACC/AHA. Guidelines for the evaluation and management of chronic heart failure[ J ]. Circulation ,2001,104:2996 - 3007.
  • 8Arnold JM, Yusulf S, Young L, et al. HOPE investigators. Preevention of heart failure in the Heart Outcomes Prevention Evaluation(HOPE) Study[J]. Circulation ,2003,107:1284 - 1290.
  • 9Hjalmarson F, Goldstein S. Effects of controlled - relase metoprolol on total mortality, hospitalization, and well - being in patients with heart failure. The Metoprolol CR/XL Randomised international trial in Congestive Heart Failure (MEEIT - HF) [ J ]. JAMA, 2000,283 :1295 - 1302.
  • 10Pitt B,Zannad F, Remme WJ, et al. The effect of spironolactione on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [J]. N Engl J Med,1999,341:709 -717.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部